Amplifying hepatic L-aspartate levels suppresses CCl4-induced liver fibrosis by reversing glucocorticoid receptor β-mediated mitochondrial malfunction

• Main Authors: Rui Su (Author), Hui-Ling Fu (Author), Qian-Xue Zhang (Author), Chen-Yan Wu (Author), Guan-Yu Yang (Author), Jun-Jie Wu (Author), Wen-Jie Cao (Author), Jin Liu (Author), Zhong-Ping Jiang (Author), Cong-Jun Xu (Author), Yong Rao (Author), Ling Huang (Author)
• Format: Book
• Published: Elsevier, 2024-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Liver fibrosis is a determinant-stage process of many chronic liver diseases and affected over 7.9 billion populations worldwide with increasing demands of ideal therapeutic agents. Discovery of active molecules with anti-hepatic fibrosis efficacies presents the most attacking filed. Here, we reveal...